arrow
J

Jameel Muzaffar

University of Birmingham
H指数:16
被引数:1,182

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to Letter to the Editor From Zhang et al: Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer

张等人的来信回复:卡博替尼联合伊匹木单抗/纳武利尤单抗治疗既往接受过治疗的分化型甲状腺癌患者

2025-04-040
OA
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer

卡博替尼联合Ipilimumab/Nivolumab治疗先前治疗的晚期分化型甲状腺癌患者

2024-08-121
OA
Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor
2024-04-051
PRE